# DESCRIPTION

## FIELD OF THE INVENTION

- define invention scope

## BACKGROUND OF THE INVENTION

- discuss glaucoma and astrocytes

## SUMMARY OF THE INVENTION

- summarize method for reducing retinal inflammation
- summarize method for reducing astrocyte transformation

## DETAILED DESCRIPTION OF THE INVENTION

- introduce background of neurodegenerative diseases
- describe role of pro-inflammatory microglia, macrophages, and A1 astrocytes
- discuss links between cytokines and glaucoma
- motivate use of glucagon-like peptide 1 receptor agonist
- describe effects of NLY01 in mouse models of Parkinson's disease
- introduce microbead-induced ocular hypertension mouse glaucoma model
- show upregulation of cytokines and A1 transformation in retina
- demonstrate prevention of A1 astrocyte formation and RGC loss
- describe therapeutic effect of NLY01 in reducing ocular inflammation
- introduce treatment of glaucoma by GLP-1R agonist administration
- describe mechanism of GLP-1R agonist in reducing retinal inflammation
- introduce treatment of glaucoma by adenoviral vector administration
- describe mechanism of adenoviral vector in reducing RGC death
- define terms used in the application
- describe scope of terms used in the application
- introduce method for reducing retinal inflammation and neuron death
- describe administration of GLP-1R agonist in reducing retinal inflammation
- introduce method for reducing production of IL-1α, TNF-α, and C1q
- describe administration of GLP-1R agonist in reducing cytokine production
- introduce method for decreasing transformation of astrocytes to A1 neurotoxic phenotype

### Pharmaceutical Compositions

- define pharmaceutical compositions
- describe pharmaceutically acceptable carriers
- list examples of carriers and diluents
- describe methods of administration
- describe formulations and ingredients
- discuss sterile injectable solutions and powders
- outline administration routes and options

### Effective Doses

- define therapeutically effective amount
- determine dosage factors
- specify dosage ranges
- illustrate administration schedules

## EXAMPLES

### Methods and Materials

- introduce experimental model
- describe mouse strains and husbandry
- outline anterior chamber injection and IOP measurement
- detail retinal cell sorting and RNA isolation
- describe quantitative PCR and ELISA procedures
- outline preparation of retinal flatmounts and immunofluorescence
- describe quantification and statistical analysis

### Elevated Intraocular Pressure Induces A1 Astrocyte Reactivity in the Retina

- induce eIOP in mice and measure IOP
- analyze A1 astrocyte reactivity and C3 production

### TNF-α, IL-1α, and C1q Contribute to Retinal Ganglion Cell Death Secondary to eIOP

- investigate role of TNF-α, IL-1α, and C1q in RGC death

### Early Retinal Inflammation is Driven by CD11b+ CD11c+ Cells and Persists Beyond IOP Re-Normalization

- measure IL-1α, TNF-α, and C1q protein levels
- analyze CD11b+ cell subpopulations and cytokine expression

### NLY01, a GLP-1R Agonist, Reduces IL-1α, TNF-α, and C1q Production by CD11b+ CD11c+ and CD11b+ CD11c− Cells and Decreases A1 Astrocyte Activation During eIOP

- test NLY01 therapy on CD11b+ cell cytokine production
- analyze A1 astrocyte activation and C3 production
- investigate NLY01's effect on NFκB phosphorylation and IκBα mRNA levels

## Discussion

- introduce glaucoma
- motivate need for new therapies
- describe role of A1 reactive astrocytes
- summarize recent work corroborating findings
- discuss transcriptomic data from DBA/2J mouse model
- highlight macrophage infiltration in glaucoma
- describe time course of IL-1α, TNF-α, and C1q upregulation
- discuss persistent inflammation after normalization of IOP
- summarize effects of NLY01 on A1 astrocyte formation
- discuss multi-hit hypothesis of RGC death
- highlight potential therapeutic benefits of NLY01

## Limitations

- discuss limitations of study

